Our team is on their way to the ESGCT conference 2025! Excited for this upcoming week full of science, talks, and inspiring discussions with the cell & gene therapy community!
Starting with the HDR workshop - talks by Isabell (‘one-pot’ PASTA) & Viktor
(BEKI) + posters by Ana, Lily, Jonas and Laura

You like engineering T cells, but you are missing the right flavor?

Check out 'one-pot' PASTA recipe 🔥🍝: www.biorxiv.org/content/10.1101/2025.09.10.675267v1

We combined a unique mix of CRISPR knock-in with serine integrases for easy-to-adopt
𝐏rogrammable
𝐀nd
𝐒ite-specific
𝐓ransgene
𝐀ddition
🧪

Lab History pt. 6 (2025)

For non-viral CAR-T cell generation with Cas12a, what is BETTER THAN DOUBLE-STRANDED DNA ?

www.cell.com/molecular-th...

Lab History pt. 5 (2025)

What is the best Knock-in strategy to make CAR-Tregs??

our answer is published in Molecular Therapy 🔗
www.cell.com/molecular-th...

Lab History pt. 4 (2024)

What could be BETTER THAN TRAC KNOCK-IN ??

CD3Z-CAR KI story, published in Blood
pmc.ncbi.nlm.nih.gov/articles/PMC...

Lab History pt. 3 (2023)

Ultra-depletion of TCR+ cells from allogeneic CAR T cells to prevent GvHD.... LOG-FOLD BETTER THAN MACS!!!

HOW? => Addition of short-lived TCR-specific CAR NK-92 cells during expansion.

Published in Blood Advances 🔗 ashpublications.org/bloodadvance...

Lab History pt. 2 (2023)
Single-step, complex non-viral CAR-T engineering: Cas12a for TRAC KI + nCas9 base editors for multiplex-KO.

=> Using orthogonal CRISPR systems for KI and KO ↓ translocations to <0.1%.

Published in Genome Biology. 🔗 link.springer.com/article/10.1...

Lab History pt. 1
2022 – 🚨 Our first paper is out! 🚨

virus-free CAR knock-in to TRAC locus of primary human T cells with CRISPR-HDR.

➡️ >50% TRAC CD19-CAR T cells through pharmacological modulation

🧬 A key step toward scalable, non-viral CAR-T cell therapies.

DOI: 10.1016/j.omtm.2022.03.018